相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling
Zhenzhen Gao et al.
BIOMEDICINE & PHARMACOTHERAPY (2013)
Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2013)
The Evolution of Cytochrome P450 Enzymes as Biocatalysts in Drug Discovery and Development
Elizabeth M. J. Gillam et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
The quality of protein of coloured fleshed potatoes
A. Peksa et al.
FOOD CHEMISTRY (2013)
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Alberto Antonicelli et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
Spared Pre-irradiated Area in Pustular Lesions Induced by Icotinib Showing Decreased Expressions of CD1a Langerhans Cells and FGFR2
Qiong Zhao et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
KRAS Mutation: Should We Test for It, and Does It Matter?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed
Naruo Yoshimura et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Icotinib: kick-starting the Chinese anticancer drug industry
D. Ross Camidge
LANCET ONCOLOGY (2013)
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi et al.
LANCET ONCOLOGY (2013)
Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
Clara Panosa et al.
PLOS ONE (2013)
Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
Fumiyoshi Yamashita et al.
PLOS ONE (2013)
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Kunihiko Kobayashi et al.
TARGETED ONCOLOGY (2013)
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
Chao Lv et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Ubiquitin Ligase Cbl-b Is Involved in Icotinib (BPI-2009H)-Induced Apoptosis and G1 Phase Arrest of EGFR Mutation-Positive Non-Small-Cell Lung Cancer
Xiaodong Mu et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer
Robert J. Cerfolio et al.
ANNALS OF THORACIC SURGERY (2012)
Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
Wei-Xiang Qi et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Song Dong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Importance of Multi-P450 Inhibition in Drug-Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
Nina Isoherranen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
Fausto Petrelli et al.
CLINICAL LUNG CANCER (2012)
Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers
Can-Jun Ruan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
Mi Young Cha et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials
Guanghui Gao et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Masayuki Takeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
Fenlai Tan et al.
LUNG CANCER (2012)
The Role of Lymphadenectomy in Lung Cancer Surgery
Antonio D'Andrilli et al.
THORACIC SURGERY CLINICS (2012)
Follow-on drugs: How far should chemists look?
Fabrizio Giordanetto et al.
DRUG DISCOVERY TODAY (2011)
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
Qiong Zhao et al.
LUNG CANCER (2011)
Competitiveness in follow-on drug R&D: a race or imitation?
Joseph A. DiMasi et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
Dongyang Liu et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2011)
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians
Wei Zhou et al.
Chinese Journal of Cancer (2011)
Development of a fractionation method for the detection and identification of oak ellagitannins in red wines
Ignacio Garcia-Estevez et al.
ANALYTICA CHIMICA ACTA (2010)
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-Ares et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies
Nikhil G. Thaker et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry
Dongyang Liu et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
ErbB/HER receptor family in breast cancer - the more we search the more we learn
M. V. Karamouzis et al.
ANNALS OF ONCOLOGY (2008)
Do enthalpy and entropy distinguish first in class from best in class?
Ernesto Freire
DRUG DISCOVERY TODAY (2008)
Oak ellagitannins suppress the phosphorylation of the epidermal growth factor receptor in human colon carcinonma cells
Diana Fridrich et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry
Zhongmin Guan et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2008)
分享论文
